Sidley represented the underwriters in the US$129.4 million initial public offering by Immuneering Corporation (NASDAQ: IMRX), a biopharmaceutical company with an emerging pipeline focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying translational bioinformatics to every stage of the drug development process. Morgan Stanley, Jefferies, Cowen, and Guggenheim Securities acted as joint book-running managers of the offering.
The Sidley team was led by Global Life Sciences partner Frank Rahmani (Palo Alto and San Francisco) and Capital Markets partner Sam Gandhi (New York), and associates Alex Csordas (New York) and Hana Lee (Palo Alto). Other critical support was provided by Life Sciences Transactions partner Tom Duley (San Francisco) and associate Elliott Blufer (Los Angeles); Employee Benefits and Executive Compensation partner Corey Perry (Chicago) and associate Richard Schneider (Chicago); FDA Regulatory partner Torrey Cope (Washington, D.C.) and associate Carlo Felizardo (Washington, D.C.); and Tax partner Rachel Kleinberg (Palo Alto) and associate Marianne Tassone (San Francisco).